Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to $10.2 million.

  • Cardiff Oncology's Cash from Investing Activities rose 20769.56% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 12149.44%. This contributed to the annual value of $13.7 million for FY2024, which is 6207.21% down from last year.
  • Latest data reveals that Cardiff Oncology reported Cash from Investing Activities of $10.2 million as of Q3 2025, which was up 20769.56% from -$5.0 million recorded in Q2 2025.
  • Cardiff Oncology's 5-year Cash from Investing Activities high stood at $18.4 million for Q1 2022, and its period low was -$111.7 million during Q1 2021.
  • In the last 5 years, Cardiff Oncology's Cash from Investing Activities had a median value of $5.2 million in 2022 and averaged -$2.8 million.
  • Within the past 5 years, the most significant YoY rise in Cardiff Oncology's Cash from Investing Activities was 532662.34% (2021), while the steepest drop was 1532807.02% (2021).
  • Cardiff Oncology's Cash from Investing Activities (Quarter) stood at -$8.8 million in 2021, then surged by 179.83% to $7.0 million in 2022, then skyrocketed by 93.18% to $13.6 million in 2023, then crashed by 66.74% to $4.5 million in 2024, then surged by 125.23% to $10.2 million in 2025.
  • Its Cash from Investing Activities stands at $10.2 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$14.6 million for Q1 2025.